These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 21220758)

  • 21. Effect of oxidative stress on antioxidant enzyme activities, homocysteine and lipoproteins in chronic kidney disease.
    Atamer A; Kocyigit Y; Ecder SA; Selek S; Ilhan N; Ecder T; Atamer Y
    J Nephrol; 2008; 21(6):924-30. PubMed ID: 19034878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.
    Tonelli M; Collins D; Robins S; Bloomfield H; Curhan GC
    Am J Kidney Dis; 2004 Nov; 44(5):832-9. PubMed ID: 15492949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperlipidemia in children with chronic renal insufficiency.
    Papadopoulou ZL; Sandler P; Tina LU; Jose PA; Calcagno PL
    Pediatr Res; 1981 Jun; 15(6):887-91. PubMed ID: 7243391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency.
    Samuelsson O; Mulec H; Knight-Gibson C; Attman PO; Kron B; Larsson R; Weiss L; Wedel H; Alaupovic P
    Nephrol Dial Transplant; 1997 Sep; 12(9):1908-15. PubMed ID: 9306342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency.
    Samuelsson O; Aurell M; Knight-Gibson C; Alaupovic P; Attman PO
    Nephron; 1993; 63(3):279-85. PubMed ID: 8446264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease.
    Attman PO; Alaupovic P; Samuelsson O
    Kidney Int Suppl; 1999 Jul; 71():S14-7. PubMed ID: 10412728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis and classification of dyslipidemia in renal disease.
    Attman PO; Samuelsson O; Alaupovic P
    Blood Purif; 1996; 14(1):49-57. PubMed ID: 8718566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dyslipoproteinemia in diabetic renal failure.
    Attman PO; Nyberg G; William-Olsson T; Knight-Gibson C; Alaupovic P
    Kidney Int; 1992 Dec; 42(6):1381-9. PubMed ID: 1474769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dialysis modalities and dyslipidemia.
    Attman PO; Samuelsson O; Johansson AC; Moberly JB; Alaupovic P
    Kidney Int Suppl; 2003 May; (84):S110-2. PubMed ID: 12694322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual PPAR α / γ Agonism Normalizes Lipoprotein Profile of Renal Dyslipidemia.
    Samuelsson O; Attman PO; Gause-Nilsson I; Svensson MK; Alaupovic P
    PPAR Res; 2013; 2013():391628. PubMed ID: 23606826
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relation of atherogenic lipoproteins with estimated glomerular filtration rate decline: a longitudinal study.
    Lin J; Khetarpal SA; Terembula K; Reilly MP; Wilson FP
    BMC Nephrol; 2015 Aug; 16():130. PubMed ID: 26238454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LpA-II:B:C:D:E: a new immunochemically-defined acute phase lipoprotein in humans.
    Bagdade JD; Jilma B; Hudgins LC; Alaupovic P; McCurdy CE
    Lipids Health Dis; 2018 May; 17(1):127. PubMed ID: 29807532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quartet of APOCs and the Different Roles They Play in Diabetes.
    Hsu CC; Kanter JE; Kothari V; Bornfeldt KE
    Arterioscler Thromb Vasc Biol; 2023 Jul; 43(7):1124-1133. PubMed ID: 37226733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging Targets for Cardiovascular Disease Prevention in Diabetes.
    Stitziel NO; Kanter JE; Bornfeldt KE
    Trends Mol Med; 2020 Aug; 26(8):744-757. PubMed ID: 32423639
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D.
    Basu A; Jenkins AJ; Stoner JA; Zhang Y; Klein RL; Lopes-Virella MF; Garvey WT; Schade DS; Wood J; Alaupovic P; Lyons TJ;
    J Lipid Res; 2018 May; 59(5):872-883. PubMed ID: 29576550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular risk factors in INPH: A prospective case-control study (the INPH-CRasH study).
    Israelsson H; Carlberg B; Wikkelsö C; Laurell K; Kahlon B; Leijon G; Eklund A; Malm J
    Neurology; 2017 Feb; 88(6):577-585. PubMed ID: 28062721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Grape seed powder improves renal failure of chronic kidney disease patients.
    Turki K; Charradi K; Boukhalfa H; Belhaj M; Limam F; Aouani E
    EXCLI J; 2016; 15():424-433. PubMed ID: 27822171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-sensitivity C-reactive protein, apolipoproteins, and residual diuresis in chronic kidney disease patients undergoing hemodialysis.
    Borges DL; Lemes HP; de Castro Ferreira V; Filho SRF
    Clin Exp Nephrol; 2016 Dec; 20(6):943-950. PubMed ID: 26768861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid dysfunction and dyslipidemia in chronic kidney disease patients.
    Khatiwada S; Rajendra KC; Gautam S; Lamsal M; Baral N
    BMC Endocr Disord; 2015 Oct; 15():65. PubMed ID: 26510920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma lipoprotein(a) levels are associated with mild renal impairment in type 2 diabetics independent of albuminuria.
    Lin J; Reilly MP; Terembula K; Wilson FP
    PLoS One; 2014; 9(12):e114397. PubMed ID: 25490096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.